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Interactions between several tumor necrosis factor (TNF)-TNF receptor (TNFR) superfamily
members that are expressed by T cells and natural killer (NK) cells and various
other cell types modulate immune responses. This review summarizes the current
understanding of how the TNF ligand-TNFR interactions 4-1BBL with 4-1BB, and GITRL
with glucocorticoid-induced TNFR-related (GITR) regulate NK cell mediated antitumor
responses and discuss its therapeutic implications.
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NATURAL KILLER CELLS
Natural killer (NK) cells are lymphocytes of the innate immune
system that kill a variety of tumors and infected cells (by bacte-
ria, parasites, and viruses) without prior sensitization to antigen
and secrete cytokines that shape adaptive immune responses
(Herberman et al., 1975; Kiessling et al., 1975; Vivier et al.,
2008). Differing from T cells, NK cells lack antigen-specific recep-
tors and bear a variety of cell surface activating and inhibitory
receptors to recognize the cells that they kill and to regulate
their functions (Figure 1A) (Lanier, 1998; Moretta et al., 2006;
Baessler et al., 2010; Placke et al., 2010). In this review I will
focus on how to exploit the inhibitory activity of tumor necro-
sis factor (TNF) receptors, 4-1BB and glucocorticoid-induced
TNFR-related (GITR) in NK anti-leukemia activity to improve
therapeutic NK cell intervention.
Major histocompatibility complex (MHC) class I-specific
inhibitory receptors are particularly important for NK cells to dis-
criminate “self” (healthy cells) from “altered self” (infected- and
transformed-cells) or “missing self” (Karre et al., 1986; Bix et al.,
1991). The MHC class I-specific inhibitory receptors include the
killer cell immunoglobulin-like receptors (KIRs) in humans, the
lectin-like Ly49 dimers in the mouse and the lectin-like CD94-
NKG2A heterodimers in both species (Vilches and Parham, 2002;
Yokoyama and Plougastel, 2003). By interacting with their respec-
tive MHC class I molecules [human leukocyte antigen (HLA)
in humans and H-2 and Qa1, in mice], these receptors deliver
inhibitory signals to the NK cell and prevent killing of healthy
cells (tolerance to self). In contrast, down-regulation or loss of
MHC class I expression (e.g., in microbe-infected cells, stressed or
injured cells, and tumors) shifts the balance toward activation and
renders target cells susceptible to NK cell-mediated lysis (Vilches
and Parham, 2002) (Diefenbach and Raulet, 2001; Lanier, 2005).
The NK cells may also express leukocyte immunoglobulin like
receptors (LILR), some of which also recognize MHC class I
ligands and deliver inhibitory signals upon engagement. There
are many activating receptors, including the natural cytotoxicity
receptors (NCRs; NKp30, NK40, NKp46), NKG2D, 2B4/CD244,
CD2, LFA-1, co-receptors such as DNAM-1, and the Fc receptor
CD16 (FcγRIIIa) that supports antibody-dependent cell-mediate
cytotoxicity (ADCC) that is involved in many monoclonal anti-
body (mAb) anti-tumor therapies (Bottino et al., 2006; Schleinitz
et al., 2008; Pegram et al., 2011). NK cells are activated by
various stimuli such as contact with dendritic cells (DC), MHC-
I-negative cells, binding of IgG-containing immune complexes,
direct engagement of NK receptors by stress-induced tumor-
associated molecules or pathogen-derived products, and several
cytokines such as interleukin (IL)-2, IL-12, IL-15, IL-18, IL-21,
and interferon (IFN)-α/β (Vivier et al., 2008). Upon activation,
NK cells proliferate, up-regulate effector molecules [e.g., per-
forin, granzymes, FasL, TNF-α, TNF-related apoptosis-inducing
ligand (TRAIL)], kill target cells, and produce cytokines (e.g.,
IFN-γ and TNF-α) and chemokines (e.g., IL-8, MCP-1, MIP1-
α, and RANTES) that influence the responses of other immune
cells (Zamai et al., 1998; Wu and Lanier, 2003; Yokoyama et al.,
2004; Vivier et al., 2008). Alterations in NK cell number or func-
tion (by an excess of inhibitory or activating signals) have been
implicated in inflammation, carcinogenesis, and autoimmune
diseases.
The TNF superfamily of ligands and receptors is critical for
building innate and adaptive immune responses against for-
eign pathogens and cancer by regulating cell death and sur-
vival in cells under T cell or NK cell attack and by providing
up- or down-regulatory effects on the killer lymphocytes them-
selves (Locksley et al., 2001; Ware, 2011). The TNF receptor
(TNFR) family has two major sub-groups, death domain (DD)-
containing receptors and TNFR-associated factor (TRAF) binding
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FIGURE 1 | (A) Interactions of inhibitory and activating NK cell receptors,
including TNF family receptors 4-1BB and GITR, with ligands expressed on
leukemia cells. Engagement of the inhibitory receptors KIR and NKG2A
with MHC class I molecules directly transmits inhibitory signals to the NK
cells to reduce killing of tumors and IFN-γ production, whereas interactions
of 4-1BB with 4-1BBL and GITR with GITRL can produce activating or
inhibitory effects depending on conditions. Here their exclusively inhibitory
effects upon interaction with leukemia cells are illustrated. Reverse
signaling (by the bound ligands 4-1BBL and GITRL) to signal the leukemia
cells induces the leukemic production of immunosuppressive cytokines
such as TGF-β, TNF-α, and IL-10, which also suppress NK cell functions.
Engagement of the activating NK cell receptors (NCRs) to their respective
ligands and NKG2D to MICA/B or ULBPs on tumors transmits activating
signals to NK cells and triggers their functions. Interactions between LFA-1
and ICAM-1 on the tumors promote cell-cell adhesion and activate NK
cells. NK cell recognition of antibody-coated tumor cells by CD16 results in
NK cell activation and tumor killing (ADCC). NK cells respond to cytokines
such as IL-2, -15, or -21 by proliferating and increasing their functions.
Activated NK cells can release lytic molecules such as perforin and
granzymes upon engagement of target cells leading to necrosis and/or
apoptosis of tumors. NK cells can also express TNF family proteins TRAIL
and FasL, which binds death domain-containing TRAILR and Fas on tumors
cells to induce tumor-cell apoptosis. (B) Therapeutic approaches to increase
NK cell anti-leukemia effects. NK cell-mediated anti-leukemia activity can be
enhanced by several approaches, including: (1) inactivation of KIR- and
NKG2A-derived inhibitory signals using blocking mAbs; (2) blocking 4-1BB
and GITR inhibitory signals using specific mAbs; (3) neutralization of 4-1BBL
and GITRL effects on leukemia by competition with 4-1BB-Ig and GITR-Ig
fusion proteins; and (4) ADCC with mAbs specific for tumor-associated
antigens; and (5) IL-15 or IL-21 stimulation of cytotoxic activity. It should be
noted that with approach 3, the R-Ig reagents may be able to stimulate the
tumor productive of TGF-β and other immunosuppressive cytokines.
receptors. The DD receptors, such as Fas (CD95), TRAIL-R1,
TRAIL-R2, and TNFR1, activate caspases via DD-containing
adaptor proteins, leading to apoptosis (Chen and Goeddel, 2002;
Ware, 2011). TRAF binding receptors, including CD27, CD40,
OX40, HVEM, CD30 and 4-1BB (CD137; TNFRSF9), and GITR
(CD357; TNFRS18), which are the subjects of this review, acti-
vate transcription factors [e.g., nuclear factor-kappa B (NF-κB)]
and are associated with cellular activation, differentiation and
survival. Various members of the TNF-TNFR superfamily are
expressed by NK cells and can regulate NK cell responses (Watts,
2005; Bekiaris et al., 2009; Croft, 2009, 2010; Steinberg et al., 2011;
Vujanovic, 2011; Rakhmilevich et al., 2012). New insights into
the functions of 4-1BB and GITR distinguish these two TNFRs as
NK regulatory receptors with dual functions, both activating and
inhibitory. Their unexpected and intriguing properties in human
NK cell-mediated anti-leukemia activity prompted this review
and my discussion of therapeutic implications of modulation of
4-1BB-4-1BBL and GITR-GITRL interactions.
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POTENTIAL FOR MANIPULATION OF NK CELLS IN TUMOR
THERAPY
Research over the last decade has shown that NK cells are a
promising tool for immunotherapy of cancers, in particular
leukemia, that can be improved further by strategic modifica-
tions. Haploidentical stem cell transplantation (SCT) in acute
myelogenous leukemia (AML), in which absence of KIR engage-
ment on donor NK cells for the specific HLA molecules of the
patients (termed KIR-HLA mismatch), produced powerful graft
vs. leukemia (GVL) effects (Ruggeri et al., 2002). The NK cell
KIR-HLA mismatches reduced risk for leukemia relapse without
increased graft vs. host disease (GVHD). Patients with multi-
ple myeloma who received haploidentical SCT also exhibited
reduction in relapse rates, a benefit that may be NK cell medi-
ated (Kroger et al., 2005). In addition, infusions of allogeneic
NK cells are able to induce clinical remission in patients with
AML (Curti et al., 2011; Nguyen et al., 2011; Miller et al.,
2005). Infusions of NK cells have also improved the treat-
ment of other cancers such as neuroblastomas, lymphomas,
melanomas, and renal, ovarian, and breast cancers (Castriconi
et al., 2007; Arai et al., 2008; Bachanova et al., 2010; Geller et al.,
2011). Furthermore, Fc-FcγR interactions in NK cell mediated
ADCC are important for the in vivo antitumor effects of the
mAbs Rituximab (anti-CD20) for lymphomas, Herceptin (anti-
Her2/neu) for breast cancers, Cetuximab (anti-EGFR) for head
and neck cancer, and anti-GD2 for neuroblastomas (Clynes et al.,
2000; Levy et al., 2011). Therefore, there is relevant in vivo ther-
apeutic anti-tumor activity of NK cells that can be enhanced
to make these cells even more important components of tumor
control.
Attempts at increasing the susceptibility of a cancer cell to
NK cell mediated lysis have focused on modulating the bal-
ance between inhibitory and activating NK cell receptor signals
using blocking antibodies for inhibitory receptors, cytokines,
and drugs. For example, blocking NK cell inhibitory recep-
tors in hematopoietic SCT is being tested in clinical trials
with a fully humanized anti-KIR monoclonal antibody (1-7F9)
(Romagne et al., 2009; Sola et al., 2009; Benson et al., 2011,
2012; Vey et al., 2012). This monoclonal antibody recognizes
KIR2D inhibitory receptors and blocks their interaction with the
HLA-C molecules, leading to NK cell-mediated lysis of leukemia
cells. However, as the recognition of MHC class I molecules
by KIRs is crucial for developing NK cells to become func-
tionally competence and discriminate “self” from “altered self”
(NK cell education or “licensing”) (Kim et al., 2005; Anfossi
et al., 2006), caution is warranted. IL-2 potently activates and
induces NK cell anti-tumor activity, but systemic administra-
tion of this cytokine is associated with life-threatening toxic-
ity (Fehniger et al., 2002). IL-15 or IL-21, which also enhance
NK cell functions, might prove to be more effective than IL-2
[e.g., IL-2 induces activation-induced cell death (AICD) of cyto-
toxic lymphocytes and expands suppressive T regulatory cells
(Tregs)] (Waldmann et al., 2001; Miller et al., 2005; Barao et al.,
2011; Denman et al., 2012; Josefowicz et al., 2012) in ensur-
ing in vivo persistence of transferred functional NK cells for
long-term control of leukemia (and of other cancers). Also, cer-
tain drugs currently used in cancer therapy, such as Bortezomib,
Lenalidomide, and Cyclosporin A have been shown to boost
NK cell functions by induction NK cell-stimulatory ligands on
tumor cells or cytokines (Poggi and Zocchi, 2005; Wang et al.,
2007; Ames et al., 2009; Benson et al., 2011). Another approach
could be the genetic modification of NK cells with tumor-specific
chimeric antigen receptors (CARs) to amplify activating signals
and induce specific killing of tumor cells. For example, cou-
pling the activating domains of the 2B4 or 4-1BB to CD19
receptors and CD3ζ has shown to markedly enhance NK cell-
mediated killing of CD19-positive leukemia cells (Imai et al.,
2005; Altvater et al., 2009). Altogether, these achievements are
encouraging observations to justify improvements in the in vivo
NK cell retention that is needed to facilitate the many new
approaches under consideration to manipulate NK cells against
cancer.
4-1BB IN NK CELLS
4-1BB is an inducible, co-stimulatory molecule expressed on acti-
vated CD4 and CD8 T cells. The majority of studies are centered
on the use of 4-1BB agonistic antibodies or of 4-1BBL to increase
the proliferation, function, and survival of T cells (Watts, 2005;
Croft, 2009). Results are encouraging with systemic administra-
tion of 4-1BB agonistic antibodies in mouse models of T cell
immunity toward tumors (Vinay and Kwon, 2012). On the basis
of these results, 4-1BB anti-tumor properties are currently being
tested in phase II clinical trials with a fully humanized 4-1BB
agonistic mAb (BMS-663513) in patients with advanced solid
malignancies and the antibody seems to have a favorable toxicity
profile (Vinay and Kwon, 2012).
4-1BB is negligible on most resting NK cells and is induced
on many of the NK cells upon activation with IL-2, IL-15,
and CD16 triggering (Lin et al., 2008; Baessler et al., 2010).
Initial studies showed that in vitro stimulation of mouse NK
cells with 4-1BB agonistic antibodies or with cell lines express-
ing 4-1BBL induced NK cell proliferation and IFN-γ secre-
tion, but without an increase of the spontaneous cytotoxicity
that is the hallmark of NK cells (Melero et al., 1998; Wilcox
et al., 2002). In vivo mouse and human xenograft tumor stud-
ies showed enhanced NK cell-mediated ADCC by 4-1BB trig-
gering. Kohrt et al. reported that sequential administration of
Rituximab (anti-CD20mAb) followed by anti-4-1BB agonistic
antibody treatment had potent anti-lymphoma activity in syn-
geneic mouse and human xenotransplanted lymphoma models
(Kohrt et al., 2011). In addition, depletion of Tregs, which are
known to suppress NK cells, could enhance anti-lymphoma
activity (Houot et al., 2009). As well, agonistic antibody trig-
gering of 4-1BB increased the response of mouse NK cells in
mice bearing human Her2-overexpressing breast tumor cells and
given Trastuzumab (anti-Her2mAb) treatment (Kohrt et al.,
2012). In addition, a recent study from Maniar et al. reported
that human 4-1BBL-positive γδT cells induced robust human
NK cell-mediated killing of tumors that are usually resistant to
NK cytolysis (e.g., lymphomas, melanomas, breast, and colon
tumors) through subsequent NKG2D recognition (Maniar et al.,
2010). These studies indicate that in this mouse and human
anti-tumor scenarios 4-1BB functioned as an activating NK cell
receptor.
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However, in sharp contrast to 4-1BB enhancements of the
NK activities listed above, in the leukemia setting, 4-1BB-4-1BBL
interactions can impair NK cell reactivity. Helmut Salih and
coworkers found that 4-1BBL was highly expressed on many
leukemias from patients with AML (23/65; 35%) and B cell
chronic lymphocytic leukemia (B-CLL) (28/89; 32%) and that
NK cells from these patients expressed 4-1BB (Baessler et al.,
2010; Buechele et al., 2012a). Signaling via 4-1BB on allogeneic
NK cells after binding to 4-1BBL-positive AML cells actually
impaired NK cell functions (both cytotoxicity and IFN-γ), which
were restored by blocking 4-1BB with specific antibodies (Baessler
et al., 2010). A reduction in direct killing and Rituximab-induced
NK cell ADCC against 4-1BBL-expressing B-CLL cells was also
observed (Buechele et al., 2012a). These results are in remark-
able contrast to the afore-mentioned 4-1BB-4-1BBL interactions
that enhanced the reactivity of human T cells against AML
cells (Houtenbos et al., 2007). Thus, 4-1BB functioned as an
inhibitory NK cell receptor when NK cells were interacting with
4-1BBL-positive leukemia cells. Whether this direct inhibition
can happen with other tumors that express 4-1BBL is presently
unknown.
There is the potential for “double inhibition” of NK activity via
cytokines as well as 4-1BBL from the leukemia cells. The ability
to signal bidirectionally is a characteristic feature of many lig-
ands of the TNF family (Eissner et al., 2004). Baessler et al. also
reported that signals via 4-1BBL into leukemia cells stimulated
the release of the immunosuppressive cytokines such as IL-10 and
TNF-α (Baessler et al., 2010). IL-10 can suppress NK cell cytokine
production (Mocellin et al., 2005) and TNF-α can induce NK
cell apoptosis (Jewett et al., 1997). In fact, NK cell reactivity
against 4-1BBL-positive leukemia cells could be restored by neu-
tralization of IL-10 or TNF-α (with Infliximab) (Baessler et al.,
2010). Overall, these findings indicate that 4-1BBL may actually
enable leukemias to evade immune surveillance by inhibiting the
anti-tumor activity of human NK cells through direct 4-1BB-4-
1BBL interactions and by inducing release of immunosuppressive
cytokines from the tumors.
How can the differences in outcome of 4-1BB triggering in
mouse vs. human NK cells and NK vs. T cells be explained? The
answer may lie in underlying differences in signaling molecules
in the NK cells. Murine and human 4-1BB cytoplasmic domains
recruit the adaptor proteins TRAF1 and 2, with 4-1BB having a
higher affinity for TRAF2 (Arch and Thompson, 1998). The asso-
ciation of 4-1BB with TRAF2 results in activation of downstream
signaling pathways, such as the NF-κB and mitogen-activated
protein kinase (MAPK) pathways, including p38 and JNK acti-
vation, ultimately leading to T and NK cell activation, cytokine
production, and cell survival (Wang et al., 2009). Human but not
mouse 4-1BB can also recruit TRAF3 (Jang et al., 1998). Of note,
TRAF3 forms heterotrimers with TRAF2 and inhibits NF-κB acti-
vation induced by TRAF2 following engagement of TNFRs such
as CD40 and OX40 (Hauer et al., 2005; Hacker et al., 2011).
Therefore, it is possible that in humans TRAF3 acts as a nega-
tive regulator of 4-1BB signaling leading to NK cell inhibition by
NF-κB inactivation. Moreover, human and mouse 4-1BB intra-
cellular domains differ by small sequences of amino acids that
might bind regulatory molecules such as phosphatases (Marvel
and Walzer, 2010). In fact, one of these motifs, present only in
human 4-1BB resembles an immuno-tyrosine inhibitory motif
(Marvel and Walzer, 2010). Reciprocally, mouse but not human
4-1BB contains the sequence Cys-X-Cys-Pro which mediates the
binding of co-receptors such as CD4 and CD8 to the protein tyro-
sine kinase, p56lck (Kim et al., 1993); this kinase is essential for the
optimal responses of T cells to antigen. For perspective, p56lck is
expressed by NK cells (Salcedo et al., 1993). The opposite out-
come of 4-1BB triggering in NK and CD8 T cells in humans can
compounded by differential expression of inhibitory receptors
(e.g., KIRs and NKG2A/B) and by heterodimerization between
TNFRmembers (i.e., OX40 and 4-1BB in T cells (Ma et al., 2005).
In summary, it is only possible now to speculate on the contribu-
tions to differences in 4-1BB effects on mouse vs. human NK cells
and NK vs. T cells. Additional studies are required and impor-
tant because the murine models may mislead human clinical
strategies.
GITR IN NK CELLS
Studies in mice have shown that GITR activation, either by anti-
GITR antibodies or by its ligand GITRL increases TCR-induced
T cell proliferation and cytokine production and rescues T cells
from anti-CD3-induced apoptosis (Watts, 2005). Consistent with
this co-stimulatory role of GITR for T cells, additional stud-
ies have shown that modulation of the GITR-GITRL interaction
with agonistic antibodies can be an effective immunotherapy for
tumors that are immunogenic for T cells (Placke et al., 2010;
Nocentini et al., 2012). Therefore, an agonistic human anti-GITR
mAb (TRX-518, TolerxR), which blocks the interaction of GITR
with its ligand and also co-stimulates T cells and enhances the
cytotoxicity of NK cells, is currently under clinical investiga-
tion for the treatment of melanoma [(Schaer et al., 2010) and
clinicaltrials.gov].
Although there is a consensus for the role of GITR in mouse
T cells, its role in NK cells is controversial. There is little infor-
mation about GITR with mouse NK cells. GITR engagement can
be activating or inhibitory to human NK cells. GITR is constitu-
tively expressed at low levels on NK cells and up-regulated after
activation with IL-2 and IL-15 (Baltz et al., 2007; Liu et al., 2008).
Hanabuchi et al. found that activated plasmacytoid DCs (pDCs)
expressing GITRL enhanced NK cell cytotoxicity and IFN-γ pro-
duction via GITR-GITRL interactions (Hanabuchi et al., 2006).
Using GITRL-expressing transfected target cells they also showed
that signaling by GITR promoted NK cell lysis in synergy with
IL-2, IFN-α, or anti-NKG2D antibodies. Therefore, GITRL can
work synergistically with other stimulants to promote NK cell
activation. In contrast, Baltz et al. reported that engagement of
GITR on activated NK cells by soluble (s) GITRL (from cultures
of tumor cells) or GITRL-Ig fusion protein or GITRL expressed
on the tumor target cells inhibited NK cell functions (cytotoxic-
ity and IFN-γ) (Baltz et al., 2007, 2008). A marked reduction of
the transcription factors c-Rel and RebB was observed, indicat-
ing that GITR negatively modulates NF-κB activity (Baltz et al.,
2007, 2008). Neutralization of sGITRL with GITR-Ig fusion pro-
teins partially restored the levels of RelB and increased NF-κB
activity and NK cell capacities (Baltz et al., 2008). Along with
this study, Liu et al. reported that GITR signaling with anti-GITR
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mAbs concurrently inhibited NK cell proliferation as a result of
blocked phosphorylation of Stat5 and Akt downstream signaling
proteins. GITR ligation also resulted in reduced NK cell cytokine
production (i.e., IFN-γ, IL-1, and IL-6) and increased NK cell
apoptosis (e.g., low expression of the anti-apoptotic proteins Bcl-
XL and Bad) (Liu et al., 2008). In aggregate, these studies indicate
that GITR has both positive and negative regulatory functions for
NK cells in vitro.
The intracellular signaling of GITR involves multiple TRAFs
as do 4-1BB. In fact, GITR signals downstream through a trimer
consisting of a single TRAF5 and two TRAF2 molecules (Schaer
et al., 2012). Available data indicate that whereas TRAF1, 2, 4,
and 5 activate NF-κB, TRAF3 antagonizes the effects of TRAF2
in NF-κB activation (Placke et al., 2010; Hacker et al., 2011).
A precedent for differential regulation mediated by different
adaptor molecules has been described for the NK cell receptor
2B4 in mice and men (Lanier, 2005); 2B4 engagement can be
stimulatory or inhibitory depending on the signaling molecules
that are associated (Roncagalli et al., 2005). Also, in the con-
text of receptors and signal transduction, structural oligomeric
differences between murine and human GITRL (e.g., primar-
ily dimers in mouse vs. trimers and superclusters in human)
(Nocentini et al., 2012) may contribute to different responses by
the receptor-bearing cells. It is clear that more information is
needed to define the mechanisms by which GITR affects NK cell
activity.
Like 4-1BBL, GITRL is capable of transducing signals into the
GITRL-expressing tumor cells (reverse signaling) after engage-
ment. Batlz et al. observed that GITRL signaling down-regulated
the expression of CD40 and CD54/ICAM-1, and induced tumor
cell production of immunosuppressive TGF-β (Baltz et al.,
2007). Since CD40 and C54 mediate activation and adhesion
of immune cells, their lower expression on tumor cells may
diminish NK cell binding to tumors and cytotoxicity. TGF-β
suppresses NK cell functions (Ghiringhelli et al., 2005; Barao
et al., 2006). Thus, GITRL expression seems to affect the inter-
action of tumor cells with the immune system by influencing
tumor cell immunogenicity and creating an immunosuppressive
cytokine microenvironment.
The Salih group reported that, besides 4-1BBL, high expres-
sion of GITRL was observed on leukemia cells in many patients
with AML (34/60; 57%) and CLL (47/60; 78%), but 4-1BB and
GITR were absent on healthy CD34+ hematopoietic stem cells
(Baessler et al., 2009; Buechele et al., 2012b). The leukemic
patients had high levels of sGITRL in their sera. These obser-
vations suggest that GITRL and 4-1BBL may be biomarkers of
increasedmalignancy. In addition, GITRwas expressed on the NK
cells of these patients. Primary AMLs expressing GITRL inhib-
ited the function (direct killing and IFN-γ) of allogeneic NK
cells (Baessler et al., 2009). Direct killing or Rituximab-induced
ADCC of B-CLL cells mediated by autologous NK cells were
also reduced by GITR triggering through cell-cell contact or
sGITRL (Buechele et al., 2012b). GITRL signaling into various
leukemia cells induced the production of TNF-α, IL-6, and IL-8,
or IL-10 (Baessler et al., 2009; Buechele et al., 2012b) that not
only enhanced proliferation and survival of leukemia cells but also
could suppress the immune system. Blocking GITR on NK cells
with anti-GITR mAbs or neutralizing sGITRL, IL-10 or TNF-α
has the potential to restore NK cell functions (direct killing,
ADCC, and IFN-γ). A recent report from Placke et al. also indi-
cated that GITRL-expressing platelet-coated tumor cells (termed
GITRL pseudoexpression) were able to inhibit NK cell function
(Placke et al., 2012). The described results indicate that GITR-
GITRL interactions contribute to evasion of leukemias from NK
immunosurveillance.
CONCLUDING REMARKS
The development of cancer is dependent on the interaction of
tumor cells with the immune system, a reciprocal process that
influences whether transformed cells are eliminated or progress
to a life-threatening disease. As NK cells emerge as therapeutic
agents for cancer treatment, it is important to define whether a
given cancer is susceptible to NK cell responses and to develop
customized therapeutic approaches that involve reduction of NK
cell suppression and/or stimulation of NK cell reactivity. Here
I reviewed what is currently known for the roles of the TNFRs
4-1BB and GITR in NK, focusing on human anti-leukemia activ-
ity. 4-1BB and GITR can apparently mediate both inhibitory and
activating signals on NK cells. With leukemias, there is an oppor-
tunity to induce a sufficient NK cell response to prevent relapses
in patients after haploidentical HSCT which unfortunately occur
in 11–48% of the patients, depending on the clinical considera-
tions (Hu et al., 2011). Many patients with leukemia have high
levels of s4-1BBL and sGITRL in their sera; therefore, it will be
important to determine whether these levels influence the final
outcome of their disease and to determine whether neutraliza-
tion of the s4-1BBL and/or sGITRL using R-Ig fusion proteins
can enhance NK cell-mediated tumor control (Figure 1B). The
use of blocking anti-4-1BB or anti-GITRmAbs to disrupt interac-
tions is another possible approach to prevent NK cell inhibition.
However, the occurrence of reverse signaling (from the R-Ig
fusion proteins) and/or potential simultaneous attenuation of T
cell responses (by blocking mAbs) after these therapeutic inter-
ventions have to be taken into account when considering the
benefits of promoting NK anti-leukemia activity. Of note, Tregs
highly express GITR, but suppression of human Tregs, in contrast
to mouse Tregs, does not seem to be inhibited by this receptor
(Placke et al., 2010). Further studies will better elucidate the dif-
ferential effects of 4-1BBL and GITRL signaling in mice and men
and in different immune situations (i.e., T cells vs. NK cells and
during tumor cell killing or during prior interactions with other
immune cells). Adjustments of the weight(s) in the balance of
activation vs. inhibition signals of NK cells have implications for
safety and efficacy of approaches to exploit 4-1BB and GITR to
treat cancer.
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